AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 80 filers reported holding AKERO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $167,337 | -92.5% | 3,584 | -93.8% | 0.00% | -100.0% |
| Q1 2023 | $2,219,233 | -30.2% | 58,004 | -0.0% | 0.01% | -33.3% |
| Q4 2022 | $3,179,715 | +162.8% | 58,024 | -54.7% | 0.01% | +200.0% |
| Q2 2022 | $1,210,000 | +120900.0% | 128,087 | +914807.1% | 0.00% | – |
| Q1 2022 | $1,000 | -99.9% | 14 | -100.0% | 0.00% | -100.0% |
| Q4 2020 | $847,000 | -28.8% | 32,830 | -15.0% | 0.00% | -33.3% |
| Q3 2020 | $1,189,000 | +59350.0% | 38,617 | +48782.3% | 0.00% | – |
| Q2 2020 | $2,000 | – | 79 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |